国产精品视频一区二区三区四,亚洲av美洲av综合av,99国内精品久久久久久久,欧美电影一区二区三区电影

官方微信|手機版

產(chǎn)品展廳

產(chǎn)品求購企業(yè)資訊會展

發(fā)布詢價單

化工儀器網(wǎng)>產(chǎn)品展廳>化工原料>生物化工醫(yī)藥>原料藥> S80048

S80048

具體成交價以合同協(xié)議為準(zhǔn)

聯(lián)系方式:何小姐查看聯(lián)系方式

聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息,謝謝!


上海源葉生物科技有限公司是一家專門從事生物技術(shù)相關(guān)產(chǎn)品研發(fā)和銷售的綜合性生命科學(xué)公司,在全體員工的不懈努力和廣大客戶的大力支持下,公司迅速成長為一家擁有生物試劑部、實驗及醫(yī)用耗材部、生命科學(xué)儀器部以及技術(shù)服務(wù)部等部門的高新技術(shù)企業(yè)。





生物試劑,ELISA試劑盒,對照品,標(biāo)準(zhǔn)品,培養(yǎng)基,透析袋,病理科耗材,實驗室耗材

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity
  • 靶點: PARP-2:2.1 nM (IC50);PARP-1:3.8 nM (IC50);V-PARP:330 nM (IC50);TANK-1:570 nM (IC50);PARP-3:1300 nM (IC50)
  • 體內(nèi)研究: Niraparib (MK-4827) is well tolerated and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is characterized by acceptable pharmacokinetics in rats with plasma clearance of 28 (mL/min)/kg, very high volume of distribution (Vdss=6.9 L/kg), long terminal half-life (t1/2=3.4 h), and excellent bioavailability, F=65%. Niraparib (MK-4827) enhances radiation response of p53 mutant Calu-6 tumor in both cases, with the single daily dose of 50 mg/kg being more effective than 25 mg/kg given twice daily
  • 參考文獻(xiàn):
    1. Jones P, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85. 2. Bridges KA, et al. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014 Jul 15;5(13):5076-86. 3. Wang L, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012 Dec;30(6):2113-20. 4. Mirza MR, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164.
  • 溶解度: DMSO  :  25  mg/mL  (78.03  mM;  Need  ultrasonic)H2O  :  <  0.1  mg l  (ultrasonic;warming;heat  to  80°c)  (insoluble)="">
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 3.121 ml 15.606 ml 31.212 ml
    5 mM 0.624 ml 3.121 ml 6.242 ml
    10 mM 0.312 ml 1.561 ml 3.121 ml
    50 mM 0.062 ml 0.312 ml 0.624 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的性,僅供客戶參考交流研究之用。


化工儀器網(wǎng)

采購商登錄
記住賬號    找回密碼
沒有賬號?免費注冊

提示

×

*您想獲取產(chǎn)品的資料:

以上可多選,勾選其他,可自行輸入要求

個人信息:

溫馨提示

該企業(yè)已關(guān)閉在線交流功能

蓬莱市| 剑川县| 宝鸡市| 泽普县| 屯留县| 三台县| 台北县| 宝鸡市| 聂荣县| 建阳市| 阿拉善盟| 河东区| 长葛市| 扶沟县| 泰兴市| 沁源县| 浠水县| 达日县| 孝义市| 阜阳市| 黄平县| 陆良县| 台州市| 富川| 吕梁市| 分宜县| 濮阳县| 郴州市| 维西| 定结县| 永寿县| 安乡县| 南华县| 延寿县| 文水县| 志丹县| 辽宁省| 唐海县| 天柱县| 惠东县| 赤峰市|